Catalyst Pharmaceuticals Inc (CPRX)
21.73
-0.01
(-0.05%)
USD |
NASDAQ |
Nov 05, 11:46
Catalyst Pharmaceuticals Cash from Financing (Quarterly): 1.157M for June 30, 2024
Cash from Financing (Quarterly) Chart
Historical Cash from Financing (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2024 | 1.157M |
| March 31, 2024 | 141.05M |
| December 31, 2023 | -0.665M |
| September 30, 2023 | -10.13M |
| June 30, 2023 | -0.214M |
| March 31, 2023 | 0.149M |
| December 31, 2022 | 2.253M |
| September 30, 2022 | 3.984M |
| June 30, 2022 | -2.992M |
| March 31, 2022 | -1.551M |
| December 31, 2021 | -2.526M |
| September 30, 2021 | -2.098M |
| June 30, 2021 | -3.707M |
| March 31, 2021 | 0.188M |
| December 31, 2020 | 0.026M |
| September 30, 2020 | 0.614M |
| June 30, 2020 | 0.036M |
| March 31, 2020 | 0.026M |
| December 31, 2019 | 0.578M |
| September 30, 2019 | 0.2561M |
| June 30, 2019 | 0.1925M |
| March 31, 2019 | 0.0893M |
| December 31, 2018 | 0.1515M |
| September 30, 2018 | 0.1045M |
| June 30, 2018 | 0.0041M |
| Date | Value |
|---|---|
| March 31, 2018 | 0.033M |
| December 31, 2017 | 54.14M |
| September 30, 2017 | 1.408M |
| June 30, 2017 | 1.805M |
| March 31, 2017 | 0.00 |
| December 31, 2016 | 0.0803M |
| September 30, 2016 | 0.00 |
| June 30, 2016 | 0.00 |
| March 31, 2016 | -0.0113M |
| December 31, 2015 | 0.0654M |
| September 30, 2015 | 0.9166M |
| June 30, 2015 | 0.113M |
| March 31, 2015 | 36.06M |
| December 31, 2014 | 1.822M |
| September 30, 2014 | 0.00 |
| June 30, 2014 | 26.73M |
| March 31, 2014 | 0.0165M |
| December 31, 2013 | 0.1898M |
| September 30, 2013 | 17.97M |
| June 30, 2013 | 0.0235M |
| March 31, 2013 | 0.00 |
| December 31, 2012 | 5.083M |
| September 30, 2012 | 5.56M |
| June 30, 2012 | 3.938M |
| March 31, 2012 | 0.00 |
Cash From Financing Definition
Cash flow from financing is a major line item of the statement of cash flows. This metric tracks the movement of cash flows for the overall financing activities of the company. A few examples of financing activities include common stock issuance, total dividends paid, and net debt issuance.
Cash from Financing (Quarterly) Range, Past 5 Years
-10.13M
Minimum
Sep 2023
141.05M
Maximum
Mar 2024
6.641M
Average
0.026M
Median
Mar 2020
Cash from Financing (Quarterly) Benchmarks
| Sarepta Therapeutics Inc | 39.92M |
| Vertex Pharmaceuticals Inc | -358.60M |
| Regenxbio Inc | -9.445M |
| Edgewise Therapeutics Inc | 1.952M |
| Entrada Therapeutics Inc | 101.37M |
Cash from Financing (Quarterly) Related Metrics
| Cash from Operations (Quarterly) | 64.14M |
| Cash from Investing (Quarterly) | -0.01M |
| Free Cash Flow | 114.96M |
| Free Cash Flow Per Share (Quarterly) | 0.5144 |
| Free Cash Flow to Equity (Quarterly) | 64.12M |
| Free Cash Flow to Firm (Quarterly) | 64.12M |
| Free Cash Flow Yield | 4.52% |